Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels

International Journal of Biological Markers

Volumn 21, Issue 1, 2006, Pages 12-19

  Gershtein, E S ^a   Scherbakov, A M ^a   Anurova, O A ^a   Krasil'nikov, M A ^a   Kushlinsky, N E ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Akt PKB; Breast cancer; ELISA; VEGF; VEGFR1; VEGFR2

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 33646183911     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4066     Document Type: Article

References (48)

1. Arboleda MJ, Lyons JF, Kabbinavar FF, et al. Overexpression of AKT2/ protein kinase B beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003; 63: 196-206.
2. El-Deiry WS. Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 2001; 3: E71-3.
3. Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002; 21: 3532-40.
4. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-98.
5. Kennedy S, Wagner A, Conzen S, et al. The Pi3kinase/Akt signalling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701-13.
6. Soderlund K, Perez-Tenorio G, Stal O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 2005; 26: 25-32.
7. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/ Akt signaling pathway. Cancer Res 2001; 61: 7349-55.
8. Chelouche-Lev D, Miller CP, Tellez C, Ruiz M, Bar-Eli M, Price JE. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004; 40: 2509-18.
9. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-6.
10. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129-35.
11. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Haves DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-8.
12. Stoica GE, Franke TF, Wellstein A, et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818-30.
13. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004; 87: 167-80.
14. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-24.
15. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001; 61: 5985-91.
16. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-17.
17. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-12.
18. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003; 22: 237-52.
19. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005; 65: 2511-5.
20. Johnston SR, Head J, Pancholi S, et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003; 9: 524-32S.
21. Liang K, Jin W, Knuefermann C, et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2003; 2: 353-60.
22. Mills GB, Kohn E, Lu Y, et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 93-104.
23. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-7.
24. Perez-Tenorio G, Stal O and members of the Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-5.
25. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-5.
26. Stal O, Perez-Tenorio G, Akerberg L, et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003; 5: R37-44.
27. Zinda MJ, Johnson MA, Paul JD, et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001; 7: 2475-9.
28. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999; 274: 21528-32.
29. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004; 10: 6779-88.
30. Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 2005; 41: 1017-25.
31. Schmitz KJ, Otterbach F, Callies R, et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 2004; 17: 15-21.
32. Schmitz KJ, Grabellus F, Callies R, et al. High expression of focal adheson kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 2005; 7: R194-203.
33. Cicenas J, Urban P, Vuaroqueaux V, et al. Increased level of phosporylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005; 7: R394-401.
34. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004; 204: 93-100.
35. Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil'nikov MA. Phospatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 1999; 287: 59-67.
36. Shcherbakov AM, Gershtein ES, Anurova OA, Kushlinsky NE. Activated protein kinase B in breast cancer. Bull Exp Biol Med 2005; 139: 570-2.
37. Bassalyk LS, Koposova TL, Muravyeva NI, et al. Trepanobiopsy as a tool for the study of the influence of presurgical treatment on the steroid receptor status of advanced breast cancer. Neoplasma 1986; 33: 245-50.
38. Amundadottirl L, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998; 16: 737-46.
39. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis, but suppresses tumor invasion. Cancer Res 2004; 64: 3171-8.
40. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-41.
41. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17: 575-88.
42. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
43. Le XF, Lammayot A, Gold D, et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalling. J Biol Chem 2005; 280: 2092-104.
44. Le XF, Pruefer F, Bast RC, Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27(Kip1) via multiple signaling pathways. Cell Cycle 2005; 4: 87-95.
45. Scherbakov AM, Onopchenko OV, Gershtein ES, Krasil'nikov MA. Coordinate activation of Akt/PKB and VEGF signaling pathways in tamoxifen-resistant breast cancer cells. Fifteenth International Congress on Anti-cancer Chemotherapy. Paris, France, Feb 9th-12th 2004: 223.
46. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-8.
47. Hoar FJ, Lip GY, Belgore F, Stonelake PS. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFlt-1) in human breast cancer. Int J Biol Markers 2004; 19: 229-35.
48. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003; 82: 147-54.